Log in

Relevant bibliographies by topics / Cetrorelix / Journal articles

To see the other types of publications on this topic, follow the link: Cetrorelix.

Journal articles on the topic 'Cetrorelix'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cetrorelix.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Finch, Ann R., Christopher J. Caunt, Stephen P. Armstrong, and Craig A. McArdle. "Plasma Membrane Expression of Gonadotropin-Releasing Hormone Receptors: Regulation by Peptide and Nonpeptide Antagonists." Molecular Endocrinology 24, no. 2 (2010): 423–35. http://dx.doi.org/10.1210/me.2009-0343.

Full text

Abstract:

Abstract Gonadotropin-releasing hormone acts via cell surface receptors but most human (h) GnRH receptors (GnRHRs) are intracellular. A membrane-permeant nonpeptide antagonist [(2S)-2-[5-[2-(2-axabicyclo[2.2.2]oct-2-yl)-1,1-dimethy-2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine (IN3)] increases hGnRHR expression at the surface, apparently by facilitating its exit from the endoplasmic reticulum. Here we have quantified GnRHR by automated imaging in HeLa cells transduced with adenovirus expressing hemagglutinin-tagged GnRHR. Consistent with an intracellul

APA, Harvard, Vancouver, ISO, and other styles

2

Inani, Anita. "Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: A prospective case control study." Journal of Community Health Management 10, no. 4 (2024): 132–36. http://dx.doi.org/10.18231/j.jchm.2023.030.

Full text

Abstract:

Because of its terrible effects, ovarian hyperstimulation syndrome (OHSS) has long piqued the interest of medical professionals. Since the syndrome is an iatrogenic condition brought on by elective ovarian stimulation in the pursuit of pregnancy, its complete prevention is imperative. The gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has been shown in some studies to be beneficial in the prevention of OHSS as well as an effective treatment for the condition. Therefore, we created a study at a hospital to find out how Cetrorelix works to prevent and treat OHSS in patients undergoi

APA, Harvard, Vancouver, ISO, and other styles

3

V. Mishra, Vineet, Priyanka H. Rane, Rohina S. Aggarwal, Sumesh Choudhary, Manisha Chhetry, and Smit B. Solanki. "Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: a prospective case control study." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 12, no. 11 (2023): 3252–56. http://dx.doi.org/10.18203/2320-1770.ijrcog20233289.

Full text

Abstract:

Background: Ovarian hyperstimulation syndrome (OHSS) has intrigued clinicians for many years because of its devastating consequences. As an iatrogenic condition resulting from elective ovarian stimulation in the quest for pregnancy, the need to completely prevent the syndrome is evident. Gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has found to be effective in treatment of OHSS and some studies have found it to be helpful in prevention of this condition. Hence, we designed a hospital-based study to investigate the effect of Cetrorelix in preventing and treating OHSS in in-vitro

APA, Harvard, Vancouver, ISO, and other styles

4

Hussein, M., M. A. Alboghdady, A. S. Almorsy, et al. "Efficacy of gonadotropin-releasing hormone antagonists in the management of patients with severe early-onset ovarian hyperstimulation syndrome." Voprosy ginekologii, akušerstva i perinatologii 21, no. 6 (2023): 105–12. http://dx.doi.org/10.20953/1726-1678-2023-6-105-112.

Full text

Abstract:

Objective. To study the efficacy of gonadotropin-releasing hormone (GnRH) antagonists in the treatment of patients with severe early-onset ovarian hyperstimulation syndrome (OHSS). Patients and methods. This study including 60 women was conducted between January 2021 and January 2023 at Al-Azhar University Maternity Hospitals and private ART centers. Approval from the Research Ethics Committee was obtained to conduct the study. Patients were randomly divided into two groups: group I (n = 30; control group) received only standard therapy for severe OHSS, group II (n = 30; study group) received

APA, Harvard, Vancouver, ISO, and other styles

5

de Boer, Hans, Marian de Man, Kim de Bruyn, and Adriaan van Sorge. "Cetrorelix suppression test to assess the source of androgen overproduction in postmenopausal hirsutism." European Journal of Endocrinology 155, no. 3 (2006): 391–93. http://dx.doi.org/10.1530/eje.1.02224.

Full text

Abstract:

A 75-year-old woman presenting with recent onset hirsutism and severely elevated serum androgen levels was evaluated to assess the source of excessive androgen production. Commonly recommended hormonal stimulation and suppression tests, and the usually employed imaging techniques were non-diagnostic. In this report, we describe a new suppression test based on the use of the GnRH receptor antagonist, cetrorelix, to determine whether androgen production was LH-dependent. Cetrorelix, administered in a daily dose of 250 μg subcutaneously, suppressed serum LH within 24 h and reduced serum androgen

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Cetrorelix beneficial in BPH." Inpharma Weekly &NA;, no. 1167 (1998): 9. http://dx.doi.org/10.2165/00128413-199811670-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mohammadnejad, Daryosh, Faeze Daghigh, and Arezou Hamzehzadeh. "Chemotherapy-Related Structural Changes in Cancer: Effect of GnRH Antagonist in the Ovarian Follicles." International Journal of Women's Health and Reproduction Sciences 10, no. 4 (2022): 214–18. http://dx.doi.org/10.15296/ijwhr.2022.36.

Full text

Abstract:

Objectives: The adverse effect of chemotherapy on the proliferation of granulosa cells has been indicated in recent studies. Gonadotropin-releasing hormone (GnRH) antagonists exert protective effects on granulosa cells against the side effects of chemotherapy. In the present study, we aimed to evaluate the impact of cetrorelix on the proliferation of ovarian granulosa cells following administration of thiotepa in the ovaries of female mice. Materials and Methods: In this experimental study, 30 adult Balb/c female mice (5-8 weeks old, weighing 24-28 g) were divided into three groups (n=10/ each

APA, Harvard, Vancouver, ISO, and other styles

8

Firmawati, Aulia, Mitra Artha Kurnia Hutabarat, Herlina Pratiwi та Alibiruni Haryo. "Expression of estrogen receptors alpha (ERs α) and folliculogenesis profile in ovary of the rats ovarian hypofunction model". Jurnal Ilmu-Ilmu Peternakan 31, № 1 (2021): 18–26. http://dx.doi.org/10.21776/ub.jiip.2021.031.01.03.

Full text

Abstract:

Ovarian hypofunction is one of the reproductive disorders that occur due to a decrease in ovarian function that causes animals to not experience heat. The purpose of this study was to determine the effect of GnRH antagonist hormone interventions on ovarian hypofunction model rats by looking at the expression of alpha ERs (ERs α) and the profile of folliculogenesis in the ovaries. This study used two groups of female Wistar strain rats, aged 8-10 weeks, bodyweight 150-180 grams and each group contained 10 animals. Intervention gave control group, without cetrorelix acetate intervention (placebo

APA, Harvard, Vancouver, ISO, and other styles

9

Sperduti, Samantha, Silvia Limoncella, Clara Lazzaretti, et al. "GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors." International Journal of Molecular Sciences 20, no. 22 (2019): 5548. http://dx.doi.org/10.3390/ijms20225548.

Full text

Abstract:

Commercial gonadotropin-releasing hormone (GnRH) antagonists differ by 1–2 amino acids and are used to inhibit gonadotropin production during assisted reproduction technologies (ART). In this study, potencies of three GnRH antagonists, Cetrorelix, Ganirelix and Teverelix, in inhibiting GnRH-mediated intracellular signaling, were compared in vitro. GnRH receptor (GnRHR)-transfected HEK293 and neuroblastoma-derived SH-SY5Y cell lines, as well as mouse pituitary LβT2 cells endogenously expressing the murine GnRHR, were treated with GnRH in the presence or absence of the antagonist. We evaluated i

APA, Harvard, Vancouver, ISO, and other styles

10

Sommer, Lieselotte, Kerstin Zanger, Thomas Dyong, et al. "Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women." European Journal of Endocrinology 131, no. 3 (1994): 280–85. http://dx.doi.org/10.1530/eje.0.1310280.

Full text

Abstract:

Sommer L, Zanger K, Dyong T, Dorn C, Luckhaus J, Diedrich K, Klingmüller D. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol 1994;131:280–5. ISSN 0804–4643 In contrast to gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists do not show any stimulatory effect on the pituitary but their clinical usage was precluded by severe side effects and high dose requirements. We report here on a 7-day treatment using the potent GnRH antagonist Cetrorelix ([Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]GnRH) on

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Cetrorelix - contraceptive or cancer therapy?" Inpharma Weekly &NA;, no. 855 (1992): 9. http://dx.doi.org/10.2165/00128413-199208550-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

WALSH, NANCY. "Cetrorelix Shows Promise in BPH." Family Practice News 38, no. 6 (2008): 28. http://dx.doi.org/10.1016/s0300-7073(08)70387-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Felberbaum, R. "Cetrorelix vs. Leuprorelin vor Endometriumresektion." Der Gynäkologe 41, no. 11 (2008): 924–26. http://dx.doi.org/10.1007/s00129-008-2268-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Reissmann, T., J. Engel, B. Kutscher, et al. "Cetrorelix < Rec INN >." Drugs of the Future 19, no. 3 (1994): 228. http://dx.doi.org/10.1358/dof.1994.019.03.238584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Handa, Mika, Tsuyoshi Takiuchi, Sumika Kawaguchi, et al. "Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve." PLOS ONE 20, no. 1 (2025): e0317103. https://doi.org/10.1371/journal.pone.0317103.

Full text

Abstract:

The judicious selection of ovulation inhibitors in ovarian stimulation protocols is crucial for the success of assisted reproductive technology (ART). Herein, we investigate the dose-dependent effects of chlormadinone acetate (CMA) and cetrorelix, two distinct ovulation inhibitors, on oocyte maturation in patients with normal ovarian reserve, using univariable and multivariable Poisson regression analyses. Patients undergoing progestin-primed ovarian stimulation (PPOS) with CMA (n = 299) or gonadotropin-releasing hormone antagonist (GnRH-ant) with cetrorelix (n = 605) during their initial in v

APA, Harvard, Vancouver, ISO, and other styles

16

Maiti, Kaushik, Da Young Oh, Jung Sun Moon, et al. "Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death." Journal of Clinical Endocrinology & Metabolism 90, no. 7 (2005): 4287–98. http://dx.doi.org/10.1210/jc.2004-1894.

Full text

Abstract:

Abstract Context: GnRH is known to directly regulate prostate cancer cell proliferation, but the precise mechanism of action of the peptide is still under investigation. Objective: This study demonstrates differential effects of GnRH-I and GnRH-II on androgen-independent human prostate cancer cells. Results: Both GnRH-I and GnRH-II increased the intracellular Ca2+ concentration ([Ca2+]i) either through Ca2+ influx from external Ca2+ source or via mobilization of Ca2+ from internal Ca2+ stores. Interestingly, the [Ca2+]i increase was mediated by activation of the ryanodine receptor but not the

APA, Harvard, Vancouver, ISO, and other styles

17

Reissmann, T. "The LHRH antagonist Cetrorelix: a review." Human Reproduction Update 6, no. 4 (2000): 322–31. http://dx.doi.org/10.1093/humupd/6.4.322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Engel, Jörg B., Ricardo E. Felberbaum, Wiebke Eilers, Stefan Polack, Olaf Ortmann, and Klaus Diedrich. "Clomiphene-induced LH surges and cetrorelix." Reproductive BioMedicine Online 5, no. 2 (2002): 109–11. http://dx.doi.org/10.1016/s1472-6483(10)61611-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

WALSH, NANCY. "Cetrorelix Shows Promise in Prostatic Hyperplasia." Internal Medicine News 41, no. 5 (2008): 36. http://dx.doi.org/10.1016/s1097-8690(08)70274-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

WALSH, NANCY. "Cetrorelix Shows Promise in Prostatic Hyperplasia." Clinical Endocrinology News 3, no. 2 (2008): 22. http://dx.doi.org/10.1016/s1558-0164(08)70063-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Cetrorelix launched in Germany and the UK." Inpharma Weekly &NA;, no. 1196 (1999): 22. http://dx.doi.org/10.2165/00128413-199911960-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Yadav, V. K., and R. Medhamurthy. "Dynamic Changes in Mitogen-Activated Protein Kinase (MAPK) Activities in the Corpus Luteum of the Bonnet Monkey (Macaca radiata) during Development, Induced Luteolysis, and Simulated Early Pregnancy: A Role for p38 MAPK in the Regulation of Luteal Function." Endocrinology 147, no. 4 (2006): 2018–27. http://dx.doi.org/10.1210/en.2005-1372.

Full text

Abstract:

Changes in MAPK activities were examined in the corpus luteum (CL) during luteolysis and pregnancy, employing GnRH antagonist (Cetrorelix)-induced luteolysis, stages of CL, and hCG treatment to mimic early pregnancy as model systems in the bonnet monkey. We hypothesized that MAPKs could serve to phosphorylate critical phosphoproteins to regulate luteal function. Analysis of several indices for structural (caspase-3 activity and DNA fragmentation) and functional (progesterone and steroidogenic acute regulatory protein expression) changes in the CL revealed that the decreased luteal function obs

APA, Harvard, Vancouver, ISO, and other styles

23

Li, Mingliang, Huapeng Li, Heqing Huang, et al. "Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS." Journal of Pharmaceutical and Biomedical Analysis 197 (April 2021): 113946. http://dx.doi.org/10.1016/j.jpba.2021.113946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Leonardi, Carlos E. P., Rodrigo A. Carrasco, Fernanda C. F. Dias, Eric M. Zwiefelhofer, Gregg P. Adams, and Jaswant Singh. "Mechanism of LH release after peripheral administration of kisspeptin in cattle." PLOS ONE 17, no. 12 (2022): e0278564. http://dx.doi.org/10.1371/journal.pone.0278564.

Full text

Abstract:

Kisspeptin modulates GnRH secretion in mammals and peripheral administration of 10-amino acid fragment of kisspeptin (Kp10) induces LH release and ovulation in cattle. Experiments were done to determine if iv administration of kisspeptin will activate GnRH neurons (i.e., after crossing the blood-brain barrier) and if pre-treatment with a GnRH receptor blocker will alter kisspeptin-induced LH release (from gonadotrophs) and ovulation. In Experiment 1, cows (n = 3 per group) were given human-Kisspeptin10 (hKp10; 3 x 15 mg iv at 60-min intervals) or normal saline and euthanized 150 min after trea

APA, Harvard, Vancouver, ISO, and other styles

25

Weinbauer, G. F., A. Limberger, H. M. Behre, and E. Nieschlag. "Can testosterone alone maintain the gonadotrophin-releasing hormone antagonist-induced suppression of spermatogenesis in the non-human primate?" Journal of Endocrinology 142, no. 3 (1994): 485–95. http://dx.doi.org/10.1677/joe.0.1420485.

Full text

Abstract:

Abstract The combination of gonadotrophin-releasing hormone (GnRH) antagonist and delayed testosterone substitution provides a promising approach towards male contraception. However, the GnRH antagonists used clinically so far cause side-effects and have to be administered continuously. We therefore used the non-human primate model to see whether the GnRH antagonist cetrorelix (which exhibits a favourable benefit-to-risk ratio in terms of anti-gonadotrophic action in normal men) induces complete and reversible suppression of spermatogenesis and whether GnRH antagonist-induced suppression of sp

APA, Harvard, Vancouver, ISO, and other styles

26

Engel, Jörg B., Lorenz Rieger, Johannes Dietl, and Arnd Hönig. "The GnRH antagonist cetrorelix: established indications and future potential." Expert Review of Obstetrics & Gynecology 2, no. 4 (2007): 431–40. http://dx.doi.org/10.1586/17474108.2.4.431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Klingmüller, D., M. Schepke, C. Enzweiler, and F. Bidlingmaier. "Hormonal responses to the new potent GnRH antagonist Cetrorelix." Acta Endocrinologica 128, no. 1 (1993): 15–18. http://dx.doi.org/10.1530/acta.0.1280015.

Full text

Abstract:

GnRH antagonists, unlike the GnRH agonists, immediately suppress gonadotropins and testosterone secretion without initial stimulatory effect. We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men. The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period. Five men served as controls. Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41% 53% and 72%, respectively, for tes

APA, Harvard, Vancouver, ISO, and other styles

28

Finas, Dominique, Daniela Hornung, Klaus Diedrich, and Askan Schultze-Mosgau. "Cetrorelix in the treatment of female infertility and endometriosis." Expert Opinion on Pharmacotherapy 7, no. 15 (2006): 2155–68. http://dx.doi.org/10.1517/14656566.7.15.2155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tur-Kaspa, Ilan, Eli Girsh, Jacob Rabinson, Efraim Zohav, Shmuel Segal, and Simon Meltzer. "Different doses of GnRH antagonist (cetrorelix) and IVF outcome." Fertility and Sterility 78 (September 2002): S252. http://dx.doi.org/10.1016/s0015-0282(02)04049-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Riethmüller-Winzen, H., A. Prothmann, Th Reissmann, M. Peukert, and J. Engel. "Safety aspects of the LHRH antagonist cetrorelix (cetrotide®)." International Journal of Gynecology & Obstetrics 70 (2000): A97. http://dx.doi.org/10.1016/s0020-7292(00)82824-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Patel, Shikha, Bhagawati Saxena, Priti Mehta, and Sarfaraz K. Niazi. "GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy." Pharmaceuticals 18, no. 1 (2024): 36. https://doi.org/10.3390/ph18010036.

Full text

Abstract:

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial therapeutic development, providing fast and reversible suppression of gonadotropins by directly blocking GnRH-R. Unlike typical GnRH agonists, these antagonists prevent the early hormonal flare, have a faster onset of action, and have a lower risk of cardiovascular problems. These characteristics qualify GnRH antagonists as revolutionary therapy for diseases

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Cetrorelix* is promising for the treatment of benign prostatic hyperplasia." Inpharma Weekly &NA;, no. 1639 (2008): 5. http://dx.doi.org/10.2165/00128413-200816390-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Roth, C., S. Leonhardt, C. Seidel, M. Lakomek, W. Wuttke, and H. Jarry. "GnRH antagonist cetrorelix prevents sexual maturation of peripubertal male rats." Experimental and Clinical Endocrinology & Diabetes 108, no. 05 (2000): 358–63. http://dx.doi.org/10.1055/s-2000-8129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Gopal, Lakshmi, Pradeepa Sudhakar, Dhanabagyam Kandaswami, and Saranya Manivannan. "Addition of gonadotropin releasing hormone antagonist for women undergoing intrauterine insemination: a randomized controlled trial." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 12, no. 4 (2023): 1101–5. http://dx.doi.org/10.18203/2320-1770.ijrcog20230821.

Full text

Abstract:

Background: Intrauterine insemination (IUI) is a widely acceptable fertility treatment modality. GnRH antagonists have been proven effective in restricting the LH surge. The aim of the study was to assess whether the addition of gonadotropin releasing hormone antagonist (Cetrorelix) would improve clinical pregnancy rate in women undergoing IUI. Methods: This prospective randomized controlled trial was conducted at a Sudha fertility center where 730 women with primary or secondary infertility were subjected to controlled ovarian stimulation with tablet letrozole 5mg once daily for 5 days and th

APA, Harvard, Vancouver, ISO, and other styles

35

Silveyra, Patricia, Paolo N. Catalano, Victoria Lux-Lantos, and Carlos Libertun. "Impact of proestrous milieu on expression of orexin receptors and prepro-orexin in rat hypothalamus and hypophysis: actions of Cetrorelix and Nembutal." American Journal of Physiology-Endocrinology and Metabolism 292, no. 3 (2007): E820—E828. http://dx.doi.org/10.1152/ajpendo.00467.2006.

Full text

Abstract:

Orexins and their receptors OX1 and OX2 regulate energy balance and the sleep-wake cycle. We studied the expression of prepro-orexin (PPO), OX1, and OX2 in brain and pituitary under the influence of the hormonal status in adult rats. Primarily, PPO, OX1, and OX2 expression was determined in Sprague-Dawley female cycling rats during proestrus and in males. Animals were killed at 2-h intervals. Anterior (AH) and mediobasal (MBH) hypothalamus, anterior pituitary (P), and frontoparietal cortex (CC) were homogenized in TRIzol, and mRNAs were obtained for screening of PPO, OX1, OX2 expression by sem

APA, Harvard, Vancouver, ISO, and other styles

36

Gonzalez-Barcena, D., R. B. Alvarez, E. P. Ochoa, et al. "Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix." Human Reproduction 12, no. 9 (1997): 2028–35. http://dx.doi.org/10.1093/humrep/12.9.2028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lin, YH, KM Seow, HJ Chen, et al. "Effect of cetrorelix dose on premature LH surge during ovarian stimulation." Reproductive BioMedicine Online 16, no. 6 (2008): 772–77. http://dx.doi.org/10.1016/s1472-6483(10)60141-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Espejo-Catena, Marita, Josefa Puertos, Pedro L. Estela, et al. "Protocolo weekend-free con cetrorelix y lutropina alfa en inseminaciones intrauterinas." Progresos de Obstetricia y Ginecología 57, no. 10 (2014): 445–50. http://dx.doi.org/10.1016/j.pog.2014.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Szucs, Kalman F., Dora Vigh, Mohsen Mirdamadi, et al. "Smooth muscle electromyography for detecting major alterations in the estrus cycle in rats." PLOS ONE 19, no. 8 (2024): e0307932. http://dx.doi.org/10.1371/journal.pone.0307932.

Full text

Abstract:

Determining the female animal cycle is crucial in preclinical studies and animal husbandry. Changes in hormone levels during the cycle affect physiological responses, including altered contractility of the visceral smooth muscle. The study aimed to identify estrus and anestrus using smooth muscle electromyographic (SMEMG) measurements, in vivo fluorescent imaging (IVIS) and in vitro organ contractility of the uterus and cecum. The study involved sexually mature female Sprague-Dawley rats, aged 10–12 weeks. The rats received a daily injection of cetrorelix acetate solution for 7 days, while ano

APA, Harvard, Vancouver, ISO, and other styles

40

Silveyra, Patricia, Victoria Lux-Lantos, and Carlos Libertun. "Both orexin receptors are expressed in rat ovaries and fluctuate with the estrous cycle: effects of orexin receptor antagonists on gonadotropins and ovulation." American Journal of Physiology-Endocrinology and Metabolism 293, no. 4 (2007): E977—E985. http://dx.doi.org/10.1152/ajpendo.00179.2007.

Full text

Abstract:

Orexins are peptides controlling feeding, sleep, and neuroendocrine functions. They are synthesized by the hypothalamus with projections throughout the brain. Orexins and their orexin 1 (OX1) and orexin 2 receptors (OX2) are present outside the central nervous system. Here the expression of preproorexin (PPO), OX1, and OX2 was studied in rat ovaries. PPO, OX1, and OX2 were determined by quantitative real-time RT-PCR in ovaries of cycling Sprague-Dawley rats on all days of the cycle. Serum hormones and food consumption were determined. Ovarian OX1 and OX2 expression was then studied after ovula

APA, Harvard, Vancouver, ISO, and other styles

41

Priyanka, S., P. Jayaram, R. Sridaran, and R. Medhamurthy. "Genome-Wide Gene Expression Analysis Reveals a Dynamic Interplay between Luteotropic and Luteolytic Factors in the Regulation of Corpus Luteum Function in the Bonnet Monkey (Macaca radiata)." Endocrinology 150, no. 3 (2008): 1473–84. http://dx.doi.org/10.1210/en.2008-0840.

Full text

Abstract:

Although LH is essential for survival and function of the corpus luteum (CL) in higher primates, luteolysis occurs during nonfertile cycles without a discernible decrease in circulating LH levels. Using genome-wide expression analysis, several experiments were performed to examine the processes of luteolysis and rescue of luteal function in monkeys. Induced luteolysis with GnRH receptor antagonist (Cetrorelix) resulted in differential regulation of 3949 genes, whereas replacement with exogenous LH (Cetrorelix plus LH) led to regulation of 4434 genes (1563 down-regulation and 2871 up-regulation

APA, Harvard, Vancouver, ISO, and other styles

42

Albano, C., J. Smitz, M. Camus, et al. "R-215. Serum and follicular fluid Cetrorelix concentrations in ovarian stimulation cycles." Human Reproduction 12, Suppl_2 (1997): 327. http://dx.doi.org/10.1093/humrep/12.suppl_2.327-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Lin, Yu-Hung, Kok-Min Seow, Heng-Ju Chen, Lee-Wen Huang, Jiann-Loung Hwang, and Chi-Ruey Tzeng. "Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol." Gynecological Endocrinology 23, no. 1 (2007): 45–49. http://dx.doi.org/10.1080/09513590601137079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Telegdy, Gyula, Masaru Tanaka, and Andrew V. Schally. "Effects of the LHRH antagonist Cetrorelix on the brain function in mice." Neuropeptides 43, no. 3 (2009): 229–34. http://dx.doi.org/10.1016/j.npep.2009.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ludwig, M., R. E. Felberbaum, K. Diedrich, W. Hamm, H. Riethmüller-Winzen, and H. Ulrich. "Cetrorelix (Cetrotide ® ) im Mehrfachgabe-Protokoll zur ovariellen Stimulation bei der IVF." Reproduktionsmedizin 16, no. 6 (2000): 390–99. http://dx.doi.org/10.1007/s004440000227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Lin, Yu-Hung, Yeong-Ray Wen, Yuanmay Chang, et al. "Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study." Fertility and Sterility 94, no. 1 (2010): 179–83. http://dx.doi.org/10.1016/j.fertnstert.2009.02.062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Hebisha, Sherif A., Banan A. Aboelazm, and H. N. Sallam. "GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome." Journal of Obstetrics and Gynecology of India 67, no. 4 (2016): 270–74. http://dx.doi.org/10.1007/s13224-016-0952-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Meirow, D. "The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice." Human Reproduction 19, no. 6 (2004): 1294–99. http://dx.doi.org/10.1093/humrep/deh257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Bukulmez, Orhan, Bruce R. Carr, Kathleen M. Doody, and Kevin J. Doody. "Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction." Fertility and Sterility 89, no. 1 (2008): 74–83. http://dx.doi.org/10.1016/j.fertnstert.2007.02.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Erb, Katharina, Klaus Junge, Birgit Pechstein, Edith Schneider, Hartmut Derendorf, and Robert Hermann. "Novel Formulations of Cetrorelix Acetate in Healthy Men: Pharmacodynamic Effects and Noncompartmental Pharmacokinetics." Journal of Clinical Pharmacology 42, no. 9 (2002): 995–1001. http://dx.doi.org/10.1177/009127000204200906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!